HRAS and neoplasm: The anti-tumoral effect of therapeutic STINGa–protein vaccine combination treatment was then assessed in TC-1 tumor—a cell line derived from mouse lung epithelial cells and transfected with HPV-16 E6/E7 and c-H-ras oncogenes.